Building a deeper Harbour

With an $85 million B round in hand, Harbour BioMed plans to advance newly in-licensed clinical programs while simultaneously building its pipeline through its internal platform and co-discovery deals.

Singapore sovereign wealth fund GIC led the round, which closed on Aug. 27. Fellow new investors China Life Private Equity Investment Company and Vertex Ventures and existing investors AdvanTech and Legend Capital also participated...